Anaplastic large cell lymphoma
MONDO:0020325Anaplastic large cell lymphoma (ALCL) is a rare and aggressive peripheral T-cell non-Hodgkin lymphoma, belonging to the group of CD30-positive lymphoproliferative disorders, which affects lymph nodes and extranodal sites. It is comprised of two sub-types, based on the expression of a protein called anaplastic lymphoma kinase (ALK): ALK positive and ALK negative ALCL.
Also known as: ALCL, CD30 Positive anaplastic large cell lymphoma, CD30 positive anaplastic large cell lymphoma, Ki-1 lymphoma, Ki-1 positive anaplastic large cell lymphoma, Ki-1+ ALCL, Ki-1+ anaplastic large cell lymphoma, anaplastic large cell lymphoma
2024 clinical trials for this condition and its sub-types, 66 tagged with Anaplastic large cell lymphoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Anaplastic large cell lymphoma
-
Can a smart immune cell with a kill switch beat tough lymphomas?
Cure Not yet recruitingThis Phase 1 trial tests a new type of cell therapy for people with relapsed or refractory CD30-positive lymphomas, including Hodgkin lymphoma and certain non-Hodgkin lymphomas. The treatment uses a patient's own immune cells that are genetically engineered to recognize and attac…
Phase 1 • Sponsor: The Methodist Hospital Research Institute • Aim: Cure
Last updated Jul 29, 2026 00:00 UTC
-
New drug cocktails aim to outsmart Hard-to-Treat T-Cell lymphomas
Disease control Not yet recruitingThis early-phase trial tests two different drug combinations for people with T-cell lymphoma that has come back or not responded to prior treatment. One group receives belinostat plus azacitidine; the other receives belinostat plus pralatrexate. The goal is to find the safest dos…
Phase 1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
New chemo cocktail aims to treat rare lymphoma without heart damage
Disease control Not yet recruitingThis phase 2 trial tests a new chemotherapy combination called CAOP for elderly patients (65+) with untreated peripheral T-cell lymphoma, a rare blood cancer. The standard treatment often causes heart damage, but this regimen replaces the heart-toxic drug with a safer one. The st…
Phase 2 • Sponsor: Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Rare lymphoma study aims to unlock secrets of treatment success
Knowledge-focused Not yet recruitingThis study will gather information from 100 people with a rare type of lymphoma called systemic anaplastic large cell lymphoma (sALCL) who have been treated with a drug combination called BV-CHP. Researchers want to see how well the treatment works in real life and understand why…
Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Knowledge-focused
Last updated Sep 11, 2026 00:00 UTC